ContraFect Corp

ContraFect Corp is a biotechnology company based in Yonkers, New York. The company employs 12 people and has generated $0.672 million in revenue. ContraFect Corp focuses on developing direct lytic agents (DLAs) like lysins and amurin peptides to combat antibiotic-resistant infections. Their therapeutic product candidates aim to address the global issue of antimicrobial-resistant infections, which contribute to an estimated 700,000 deaths annually. Their lysin-based therapies utilize recombinantly produced antimicrobial proteins that rapidly kill bacteria, eradicate biofilms, and enhance the effectiveness of conventional antibiotics. Amurin peptides, another class of DLAs, demonstrate broad-spectrum activity against various antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacter species. ContraFect Corp's lead lysin candidate, exebacase, has successfully completed a Phase 2 clinical trial for treating Staph aureus bacteremia, including endocarditis. Currently undergoing a pivotal Phase 3 clinical study, exebacase holds Breakthrough Therapy designation from the FDA for treating MRSA bloodstream infections, including right-sided endocarditis, when combined with standard-of-care anti-staphylococcal antibiotics in adult patients.